Drug resistance in glioblastoma: A mini review

Neurochemical Research

Volumn 37, Issue 6, 2012, Pages 1192-1200

  Haar, Catherine P ^a   Hebbar, Preetha ^a   Wallace, Gerald C ^a   Das, Arabinda ^a   Vandergrift III, William A ^a   Smith, Joshua A ^a   Giglio, Pierre ^a   Patel, Sunil J ^a   Ray, Swapan K ^b   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alternative therapies; Glioblastoma multiforme; Glioblastoma stem cells; Hypoxia inducible factors; MiRNAs; Multidrug resistance; P Glycoprotein

Indexed keywords

ABC TRANSPORTER; ALLYL SULFIDE; ANTIESTROGEN; ANTIHYPERTENSIVE AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; DEXNIGULDIPINE; DIALLYL DISULFIDE; DIALLYL TRISULFIDE; DOXORUBICIN; ELACRIDAR; ERLOTINIB; FLAVONOID; FLUOROURACIL; FOTEMUSTINE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; ORGANOSULFUR DERIVATIVE; PACLITAXEL; RETINOID; SMALL INTERFERING RNA; TARIQUIDAR; TEMOZOLOMIDE; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODOR; VINCRISTINE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CELL HYPOXIA; CENTRAL NERVOUS SYSTEM; DNA REPAIR; DRUG MEGADOSE; DRUG TARGETING; DRUG TRANSPORT; GLIOBLASTOMA; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SOLID TUMOR; SURGICAL TECHNIQUE; TUMOR CELL;

EID: 84862835220     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0701-1     Document Type: Review

References (67)

1. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P (2011) Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38(2):243-253
2. Weller M (2011) Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly 141:w13210
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466
4. Goldie JH (2001) Drug resistance in cancer: a perspective. Cancer Metastasis Rev 20(1-2):63-68 (Pubitemid 34074680)
5. Molnar J, Engi H, Hohmann J, Molnar P, Deli J, Wesolowska O, Michalak K, Wang Q (2010) Reversal of multidrug resistance by natural substances from plants. Curr Top Med Chem 10(17): 1757-1768
6. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94(1):15-21 (Pubitemid 36575852)
7. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O (2010) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs (Epub ahead of print). PMID: 2096 3470
8. Zhao P, Zhang YZ, Sun MZ (2005) Regulatory effect of small interfering RNA targeting multidrug resistant protein 1 on chemosensitivity of human multiforme glioblastoma cell line BT325. Ai Zheng 24(12):1436-1441
9. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627 (Pubitemid 34177898)
10. Hubensack M, Muller C, Hocherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134(5):597-607 (Pubitemid 351422612)
11. Wartenberg M, Richter M, Datchev A, Gunther S, Milosevic N, Bekhite MM, Figulla HR, Aran JM, Petriz J, Sauer H (2010) Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem 109(2):434-446
12. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65(2):613-621
13. Rittierodt M, Tschernig T, Harada K (2004) Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 71(3):123-128 (Pubitemid 38437706)
14. Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28(2 Suppl 8):29-35 (Pubitemid 32522235)
15. Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM (2009) Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol 2(3):263-284
16. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307
17. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62(12):3387-3394 (Pubitemid 34651384)
18. Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1(5):453-458
19. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18(6):1254-1259 (Pubitemid 30159843)
20. Blagosklonny MV (2005) How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 4(12):1307-1310 (Pubitemid 43131171)
21. Dai S, Huang ML, Hsu CY, Chao KS (2003) Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55(4):1027-1036 (Pubitemid 36287007)
22. Lin MI, Sessa WC (2004) Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 6(6):529-531 (Pubitemid 40017694)
23. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, Zhong H (2001) The metabolism of tumours: 70 years later. Novartis Found Symp 240:251-260 discussion 260-254
24. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD (2010) Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 78(2):103-114
25. Suri V, Jha P, Sharma MC, Sarkar C (2011) O6-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status. Neurol India 59(2):229-235
26. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13(7): 2038-2045 (Pubitemid 46649870)
27. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189-4199
28. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous doseintense temozolomide in recurrent malignant glioma: rescue study. J Clin Oncol 28(12):2051-2057
29. Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A (2010) Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? J Neurooncol 100(2): 311-319
30. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352:255-264
31. Li Y, Li W, Yang Y, Lu Y, He C, Hu G, Liu H, Chen J, He J, Yu H (2009) MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286:13-18
32. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3(1):17-26 (Pubitemid 38088695)
33. Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S (2010) Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell 1(7):638-655
34. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015): 396-401 (Pubitemid 39551674)
35. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS (2009) Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69(18):7243-7251
36. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843-7848 (Pubitemid 44299144)
37. Carrassa L, Damia G (2011) Unleashing Chk1 in cancer therapy. Cell Cycle 10(13):2121-2128
38. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN, Bao S (2011) L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 30(5):800-813
39. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101(39):14228-14233 (Pubitemid 39305058)
40. Sul J, Fine HA (2010) Malignant gliomas: new translational therapies. Mt Sinai J Med 77(6):655-666
41. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, Su Q, Kotliarov Y, Lee J, Zhang W, Fine HA (2008) Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29(5): 918-925 (Pubitemid 351982234)
42. George J, Banik NL, Ray SK (2009) Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res 34(1):66-78
43. George J, Banik NL, Ray SK (2009) Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth. J Cell Mol Med 13(10):4205-4218
44. Bansal T, Jaggi M, Khar RK, Talegaonkar S (2009) Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12(1):46-78
45. Morris ME, Zhang S (2006) Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78(18):2116-2130
46. Das A, Banik NL, Ray SK (2010) Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 116(1):164-176
47. Zhang Y, Vareed SK, Nair MG (2005) Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life Sci 76(13):1465-1472 (Pubitemid 40164775)
48. Vargo MA, Voss OH, Poustka F, Cardounel AJ, Grotewold E, Doseff AI (2006) Apigenin-induced-apoptosis is mediated by the activation of PKCdelta and caspases in leukemia cells. Biochem Pharmacol 72(6):681-692 (Pubitemid 44233544)
49. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546:121-165 (Pubitemid 40103418)
50. George J, Banik NL, Ray SK (2010) Genistein induces receptor and mitochondrial pathways and increases apoptosis during Bcl-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. J Neurosci Res 88(4):877-886
51. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS (2007) The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67(20):9809-9816 (Pubitemid 47621228)
52. Chen TC, Wang W, Golden EB, Thomas S, Sivakumar W, Hofman FM, Louie SG, Schonthal AH (2011) Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 302(2): 100-108
53. Demeule M, Brossard M, Page M, Gingras D, Beliveau R (2000) Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 1478(1):51-60 (Pubitemid 30136138)
54. Lamy S, Lafleur R, Bedard V, Moghrabi A, Barrette S, Gingras D, Beliveau R (2007) Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system. J Cell Biochem 100(1):100-111 (Pubitemid 44958182)
55. Das A, Banik NL, Ray SK (2008) N-(4-Hydroxyphenyl) retinamide induced both differentiation and apoptosis in human glioblastoma T98G and U87MG cells. Brain Res 1227:207-215
56. Ulukaya E, Pirianov G, Kurt MA, Wood EJ, Mehmet H (2003) Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ 10(7):856-859 (Pubitemid 36850248)
57. Lippman SM, Lotan R (2000) Advances in the development of retinoids as chemopreventive agents. J Nutr 130(2S Suppl): 479S-482S (Pubitemid 30073777)
58. Mellai M, Caldera V, Patrucco A, Annovazzi L, Schiffer D (2008) Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis. Anticancer Res 28(1A): 109-118 (Pubitemid 351362888)
59. George J, Banik NL, Ray SK (2010) Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo. Neuro Oncol 12(11):1088-1101
60. Das A, Banik NL, Ray SK (2009) Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells. Neurochem Res 34(1):87-101
61. Das A, Banik NL, Ray SK (2009) Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells. Int J Oncol 34(3):757-765
62. Mukherjee P, Abate LE, Seyfried TN (2004) Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10(16):5622-5629 (Pubitemid 39100504)
63. Marsh J, Mukherjee P, Seyfried TN (2008) Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res 14(23): 7751-7762
64. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 4:5
65. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, Seyfried TN (2010) Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab (Lond) 7:33
66. Das A, Banik NL, Ray SK (2007) Garlic compounds generate reactive oxygen species leading to activation of stress kinases and cysteine proteases for apoptosis in human glioblastoma T98G and U87MG cells. Cancer 110(5):1083-1095 (Pubitemid 47312875)
67. Seyfried TN, Shelton LM, Mukherjee P (2010) Does the existing standard of care increase glioblastoma energy metabolism? Lancet Oncol 11(9):811-813